Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Sangamo Therapeutics, Inc.

< Previous 1 2 Next >
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers PFE SGMO
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Tickers SGMO
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.